[en] A number of coumarins exhibit interesting pharmacological activities and are therefore of therapeutic use. We report here the synthesis and the structural analysis of new N-substituted 4-amino-3-(2-methylbenzyl)coumarins (compounds 8a-8e) that present structural analogies with estrothiazine and 11- or 7-substituted 17ß-estradiol. These derivatives were tested with respect to estrogenic activity on the estrogen receptor positive (ER+) human MCF-7 breast cancer cell line. Two of the reported compounds (8a and 8b) stimulated specifically the proliferation of MCF-7 cells, but not that of estrogen receptor negative (ER-) human MDA-MB-231 breast cancer cells, suggesting that their mitogenic activity is mediated by ER. Accordingly, the stimulating effect of 8a and 8b was suppressed by the pure antiestrogen fulvestrant. Besides, 8a and 8b induced ER down-regulation similar to that produced by classical ER agonists or pure antagonists. The effects of the compounds under study on ER-mediated transcription were assessed on (ER+) MVLN cells, that is, MCF-7 cells stably transfected with a pVit-tk-Luc reporter plasmid. Derivatives 8a and 8b, and surprisingly compound 8c, enhanced ER-mediated gene transactivation in that model. Finally, no coumarin was able to compete with tritiated 17ß-estradiol ([3H]E2) for ER binding, suggesting unconventional interactions with the receptor, such as interactions with the second binding pocket or with the coactivator-binding region. To conclude, observations performed in this study on compound 8c reveal that estrogenic activity can be dissociated from enhancement of cell proliferation. Furthermore, ERE-driven transactivation of transcription seems to be a condition necessary, but not sufficient, for estrogen-induced stimulation of cell growth.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Jacquot, Yves
Laïos, Ioanna
Cleeren, Anny
Nonclercq, Denis ; Université de Mons > Faculté de Médecine et de Pharmacie > Service d'Histologie
Bravic G., Gaultier J., and Hauw C. C.R. Acad. Sci. Paris 267 (1968) 1790
McEvoy M.T., and Stern R.S. Pharmacol. Ther. 34 (1987) 75
Nettleton D.E. Drugs Future 34 (1996) 1257
Hoeksema H., Caron E.L., and Hinman J.W. J. Am. Chem. Soc. 78 (1956) 2019
Refouvelet B., Guyon C., Jacquot Y., Girard C., Fein H., Bévalot F., Robert J.-F., Heyd B., Mantion G., Richert L., and Xicluna A. Eur. J. Med. Chem. 39 (2004) 931
Taniguchi M., Xiao Y.-Q., Liu X.-H., Yabu A., Hada Y., Guo L.-Q., Yamazoe Y., and Baba K. Chem. Pharm. Bull. 47 (1999) 713
Livingston A.L., Bickoff E.M., Lundin R.E., and Jurd L. Tetrahedron 20 (1964) 1963
Jacquot Y., Rojaz C., Refouvelet B., Robert J.-F., Leclercq G., and Xicluna A. Mini-Rev. Med. Chem. 3 (2003) 387
Roelens F., Huvaere K., Dhooge W., van Cleemput M., Comhaire F., and De Keukeleire D. Eur. J. Med. Chem. 40 (2005) 1042
Noeldner M., Hauer H., and Chatterjee S.S. Drugs Future 21 (1996) 779
Usui T. Endocrine J. 53 (2006) 7
Jacquot Y., Refouvelet B., Bermont L., Adessi G.L., Leclercq G., and Xicluna A. Pharmazie 57 (2002) 233
Jacquot Y., Bermont L., Giorgi H., Refouvelet B., Adessi G.L., Daubrosse E., and Xicluna A. Eur. J. Med. Chem. 36 (2001) 127
Jacquot Y., Cleeren A., Laios I., Ma Y., Boulhadour A., Bermont L., Refouvelet B., Adessi G., Leclercq G., and Xicluna A. Biol. Pharm. Bull. 25 (2002) 335
Tabakovic K., Tabakovic I., Ajdini N., and Leci O. Synthesis (1987) 308
Ivanov I.C., Karagiosov S.K., and Manolov I. Arch. Pharm. (Weinheim) 324 (1991) 61
Vanhaelen M., and Vanhaelen-Fastre R. Pharm. Acta Helv. 51 (1976) 307
Traven F.V., Negrebetsky V.V., Vorobjeva L.I., and Carberry E.A. Can. J. Med. 75 (1997) 377
Traven F.V., Manaev A.V., Safronova O.B., and Chibisova T.A. J. Elec. Spectrosc. Relat. Phenom. 122 (2002) 47
Schroeder C.H., Titus E.D., and Link K.P. J. Am. Chem. Soc. 79 (1957) 3291
Cremer D., and Pople J.A. J. Am. Chem. Soc. 95 (1975) 1354
Anstead G.M., Carlson K.E., and Katzenellenbogen J.A. Steroids 62 (1997) 268
Tedesco R., Katzenellenbogen J.A., and Napolitano E. Bioorg. Med. Chem. Lett. 7 (1997) 2919
Jin L., Borrás M., Lacroix M., Legros N., and Leclercq G. Steroids 60 (1995) 512
El-Khissiin A., and Leclercq G. FEBS Lett. 448 (1999) 160
Laïos I., Journé F., Nonclercq D., Vidal D.S., Toillon R.-A., Laurent G., and Leclercq G. J. Steroid Biochem. Mol. Biol. 94 (2005) 347
Journé F., Body J.-J., Leclercq G., Nonclercq D., and Laurent G. Breast Cancer Res. Treat. 86 (2004) 39
Nonclercq D., Journé F., Body J.-J., Leclercq G., and Laurent G. Mol. Cell. Endocrinol. 227 (2004) 53
Wijayaratne A.L., and McDonnell D.P. J. Biol. Chem. 143 (2002) 35684
Blazejewski J.-C., Wilmshurst M.P., Popkin M.D., Wakselman C., Laurent G., Nonclercq D., Cleeren A., Ma Y., Seo H.-S., and Leclercq G. Bioorg. Med. Chem. 11 (2003) 335
Kekenes-Huskey P.M., Muegge I., von Rauch M., Gust R., and Knapp E.-W. Bioorg. Med. Chem. 12 (2004) 6527
Lonard D.M., Nawaz Z., Smith C.L., and O'Malley B.W. Mol. Cell 5 (2000) 939
Alarid E.T., Preisler-Mashek M., and Solodin N.M. Endocrinology 144 (2003) 3469
Fan M., Park A., and Nephew K.P. Mol. Endocrinol. 19 (2005) 2901
van Hoorn W.P. J. Med. Chem. 45 (2002) 584
Wang Y., Chirgadze N.Y., Briggs S.L., Khan S., Jensen E.V., and Burris T.P. Proc. Natl. Acad. Sci. U.S.A. 103 (2006) 9908
Rodriguez A.L., Tamrazi A., Collins M.L., and Katzenellenbogen J.A. J. Med. Chem. 47 (2004) 600
Blessing R.H. Acta Cryst. A51 (1995) 33
Sheldrick G.M. SHELXS-86, Computer Program for Structure Solution (1986), University of Gottingen, Germany
Sheldrick G.M. SHELXL-97, Computer Program for Structure Refinement (1997), University of Gottingen, Germany
Brandenburg K., and Berndt M. Diamond™ (1999), Crystal Impact GbR, Bonn, Germany
Journé F., Chaboteaux C., Dumon J.-C., Leclercq G., Laurent G., and Body J.-J. Br. J. Cancer 91 (2004) 1703
Pons M., Cagne D., Nicolas J.C., and Mehtali M. Biotechniques 9 (1990) 450
Demirpence E., Duchesne M.J., Badia E., Gagne D., and Pons M. J. Steroid Biochem. Mol. Biol. 46 (1993) 355